Diet + Semaglutide for Non-Alcoholic Fatty Liver Disease
(METAfoie Trial)

Recruiting in Palo Alto (17 mi)

Overseen byFannie Lajeunesse-Trempe, MD., Ph.D.

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

No Placebo Group

Trial Summary

What is the purpose of this trial?The goal of this clinical trial is to improve the treatment of hepatic steatosis associated with obesity with pharmacological and nutritionnal approaches. The main question it aims to answer is: Does an individualized nutritionnal approach with a dietician combined with medication targeting obesity is the most efficient way to treat hepatic steatosis associated with obesity? Participants will either participate in one of three groups: * Nutrition: Participant will only have a regular follow-up with a registered dietician; * Nutrition + Semaglutide: Participants will start a new medication targeting obesity and will have a regular follow-up with a registered dietician; * Semaglutide: Participants will start a new medication targeting obesity.

Eligibility Criteria

This trial is for individuals with fatty liver disease linked to diabetes, obesity, or non-alcoholic causes. Participants should be willing to follow a diet plan or take a medication called semaglutide, or both. The study excludes details on specific inclusion and exclusion criteria.

Inclusion Criteria

My liver has moderate to severe fat buildup.

Body mass index between 30 and 50 kg/m2

Exclusion Criteria

I have taken antibiotics in the last 3 months.

Capsulated probiotics consumption

Pregnancy

+7 more

Participant Groups

The trial tests if combining an individualized diet plan from a dietician with semaglutide (a drug targeting obesity) is more effective in treating fatty liver associated with obesity than either approach alone. There are three groups: diet only, diet plus semaglutide, and semaglutide only.

3Treatment groups

Active Control

Group I: NutritionActive Control1 Intervention

This arm will only participate in an individualized nutritionnal approach.

Group II: Nutrition + SemaglutideActive Control2 Interventions

This arm will initiate a pharmacological intervention to treat obesity (Semaglutide) and will participate in an individualized nutritionnal approach.

Group III: SemaglutideActive Control1 Intervention

This arm will only initiate a pharmacological intervention to treat obesity (Semaglutide)